Lantern Pharma's collaboration with Bielefeld University to develop novel ADCs using its AI platform RADR has the potential to create new revenue streams and strengthen its position in the growing ADC market, which is projected to reach $14 billion by 2027. Additionally, Lantern will receive an exclusive option to license intellectual property from the collaboration, which could further enhance its product portfolio and market presence.